Perimenopause is not a side note before menopause, it is the stage where symptoms start, cycles shift and treatment decisions should begin. UK guidance already treats menopause-associated symptoms in women aged 45 and over as a clinical diagnosis, not a blood test result, which matters because the window for symptom relief and bone protection opens before periods have stopped.
Perimenopause is the point to name, not ignore
In UK practice, you do not have to wait for 12 months without a period before asking for help. The NHS says menopause and perimenopause usually affect women between 45 and 55, but they can begin earlier, and symptoms that are affecting daily life, work, sleep or wellbeing deserve review. If your periods stop before 45, that is a separate conversation with your GP; if you have any bleeding after menopause, it needs checking.
NICE’s diagnostic standard is straightforward: in otherwise healthy women aged 45 or over with typical symptoms, perimenopause or menopause can be identified on symptoms alone, without confirmatory laboratory tests. That is a practical point many women still do not hear early enough, and it is exactly why the transition should be discussed while periods are still changing, not after the fact.
The symptom map is wider than hot flushes
The useful part of the explainer is its plain list of symptoms, because menopause does not announce itself in one fixed way. Hot flushes, sleep disruption, mood changes, brain fog, joint aches and vaginal dryness can appear in different combinations, and NHS guidance also notes that the pattern of periods can change in perimenopause, becoming heavier, lighter, more frequent or less frequent. Some symptoms can continue after menopause has ended, which is why there is no single menopause experience.
That variability is the trap. Women often normalise poor sleep, low mood or aching joints until the pattern becomes hard to ignore, then arrive at primary care only once symptoms are affecting work, relationships or training. The clinical task is to connect those changes to the hormone transition early, rather than treating each complaint as a separate problem with no common cause.
HRT fear changed the conversation, but not the need for it
The shadow over HRT still traces back to the Women’s Health Initiative findings in 2002, which pushed years of caution and underuse. The US regulator has since moved to remove broad boxed warnings from menopausal hormone therapy products and has approved label changes to clarify risk considerations, including the removal of boxed-warning statements about cardiovascular disease, breast cancer and probable dementia from six products. FDA labels also state that the timing of initiation relative to menopause affects the risk-benefit profile.
That is a US regulatory change, not a new NHS rule. In the UK, NICE already frames menopause treatment as individualised care: people aged 40 and over should have management options discussed, and cognitive behavioural therapy is listed as an option alongside or instead of HRT for vasomotor symptoms, sleep problems or depressive symptoms. The message for primary care is less about slogans than about matching treatment to symptom burden, age and preference.
Bone health belongs in perimenopause, not after a fracture
The prevention message is the most important part of the story. NHS guidance says weight-bearing and resistance exercise are particularly important for improving bone density and preventing osteoporosis, and adults aged 19 to 64 should do muscle-strengthening activities on two or more days a week. The same NHS advice points women towards calcium-rich foods and regular exercise rather than treating movement as an optional extra.
NICE’s osteoporosis guidance adds the risk context that makes this urgent: early menopause, vitamin D deficiency, low calcium intake, low physical activity, smoking and excess alcohol are all risk factors for osteoporosis. NICE also notes that HRT can be considered in younger postmenopausal women to reduce osteoporotic fracture risk and relieve menopausal symptoms. That is the missed opportunity in midlife care, because the bone conversation should start while symptoms are being recognised, not after fracture risk has already risen.
What to ask in primary care
Make the appointment specific. Ask whether your periods and symptoms fit perimenopause, whether you can be diagnosed clinically if you are 45 or over, what your treatment options are, and whether your bone-risk factors mean prevention should start now. If you are having bleeding after 12 months without a period, ask for the urgent route for assessment, not reassurance.
- Do my symptoms and period changes fit perimenopause, or do they need another explanation?
- If I am 45 or older, can this be diagnosed on symptoms alone, without blood tests?
- Is HRT suitable for my symptom pattern, and should CBT also be part of the discussion for sleep, mood or hot flushes?
- Do early menopause, low calcium intake, vitamin D deficiency, smoking, alcohol intake or low activity change my bone plan?
The practical shift is simple: name the transition early, treat symptoms that are already disrupting life, and use midlife appointments to protect bones while there is still time to change the trajectory. That is the part of menopause care the UK can act on now.